Galectin Therapeutics (NASDAQ:GALT) had its price target cut by Roth Capital from $10.00 to $3.00 in a report released on Thursday. Roth Capital’s price target indicates a potential upside of 94.81% from the stock’s previous close.
Other analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price (up previously from $6.00) on shares of Galectin Therapeutics in a research note on Thursday. ValuEngine downgraded Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 21st. Seaport Global Securities reiterated a “buy” rating and set a $5.00 price target on shares of Galectin Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $4.55.
Shares of Galectin Therapeutics (NASDAQ:GALT) traded down $0.18 during mid-day trading on Thursday, hitting $1.54. The stock had a trading volume of 1,401,000 shares, compared to its average volume of 393,419. Galectin Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. sell-side analysts anticipate that Galectin Therapeutics will post -0.52 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the stock. Northern Trust Corp increased its holdings in shares of Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after purchasing an additional 3,176 shares during the last quarter. Virtu KCG Holdings LLC increased its stake in Galectin Therapeutics by 24.4% during the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock worth $264,000 after acquiring an additional 21,008 shares during the last quarter. Advisor Group Inc. increased its stake in Galectin Therapeutics by 10.4% during the second quarter. Advisor Group Inc. now owns 484,000 shares of the company’s stock worth $1,191,000 after acquiring an additional 45,700 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Galectin Therapeutics by 18.2% during the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock worth $2,144,000 after acquiring an additional 134,165 shares during the last quarter. 11.07% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2017/12/07/galectin-therapeutics-galt-price-target-lowered-to-3-00-at-roth-capital.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.